Lei Liu

The paper analyzes wound-repair modules in tumors to identify heterogeneous niches and conditional immunotherapy associations.

This study shows that Syndecan-4 has both HS-dependent and HS-independent effects on Aβ amyloid homeostasis, reducing amyloid deposition in a mouse model.

The paper discovers abundant nanoscale lymphatic-like vessels in brain parenchyma of mice and humans, suggesting a previously unrecognized system for metabolic waste clearance.

This study shows that OGA inhibitors impair synaptic plasticity and cause synaptotoxic effects in mouse hippocampal slices, suggesting potential risks for Alzheimer's disease therapies.

The paper develops and validates CNS-tau-specific monoclonal antibodies for use in neuropathology and plasma biomarker assays across Alzheimer's disease and primary tauopathies.

The paper assesses the pathogenicity of PSEN2 variants by comparing Aβ production and homology to PSEN1 variants, finding correlations with age at symptom onset.

This study identifies fibrinogen as a plasma protein binding partner for lecanemab biosimilar, suggesting it may affect drug half-life and free antibody levels in Alzheimer's disease therapy.

The paper quantifies Aβ production from PSEN1 variants and links it to clinical and biomarker progression in ADAD, showing strong associations with disease trajectories.

The paper reports the presence of abundant Aβ fibrils in aqueous extracts from Alzheimer's disease brains, with structures identical to those in amyloid plaques.

This paper shows that METTL3 promotes hepatic fibrosis by suppressing GPR161 through m6A-YTHDF2 modification, and its depletion alleviates fibrosis by stabilizing GPR161 and inhibiting Hedgehog pathway activation.